Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radiation for prostate cancer.

G M Duchesne1

  • 1Monash University, Melbourne, Australia. gillian.duchesne@med.monash.edu.au

The Lancet. Oncology
|March 22, 2002
PubMed
Summary
This summary is machine-generated.

Technological advances in radiotherapy for prostate cancer enable dose escalation, reducing normal tissue damage and potentially improving tumor control. Evidence suggests this approach offers survival rates comparable to surgery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The development of practice standards for radiation oncology in Australia: a tripartite approach.

Clinical oncology (Royal College of Radiologists (Great Britain))·2015
Same author

Patient-reported complications from fiducial marker implantation for prostate image-guided radiotherapy.

The British journal of radiology·2012
Same author

Prospective development of an individualised predictive model for treatment coverage using offline cone beam computed tomography surrogate measures in post-prostatectomy radiotherapy.

Journal of medical imaging and radiation oncology·2009
Same author

Implementation of daily image-guided radiation therapy using an in-room CT scanner for prostate cancer isocentre localization.

Journal of medical imaging and radiation oncology·2009
Same author

A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09.

International journal of radiation oncology, biology, physics·2000
Same author

Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1999
Same journal

New report sheds light on cancer disparities in the USA.

The Lancet. Oncology·2026
Same journal

Review highlights gaps in South Africa's cancer care.

The Lancet. Oncology·2026
Same journal

Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial.

The Lancet. Oncology·2026
Same journal

Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026
Same journal

Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology.

The Lancet. Oncology·2026
Same journal

European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine.

The Lancet. Oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Radiation Oncology
  • Medical Physics

Background:

  • Conventional radiotherapy for localized prostate cancer faces challenges in balancing tumor control with normal tissue damage.
  • Technological advancements permit minimizing radiation exposure to healthy tissues.
  • Reduced normal tissue toxicity allows for dose escalation, potentially enhancing anti-tumor efficacy.

Purpose of the Study:

  • To review methods for dose escalation in prostate cancer radiotherapy.
  • To evaluate the safety and efficacy of dose-escalated radiotherapy compared to conventional treatments.
  • To assess the impact of dose escalation on patient outcomes, including survival rates.

Main Methods:

  • Discussion of techniques used for dose escalation in prostate cancer radiotherapy.

Related Experiment Videos

  • Review of existing evidence on the safety and efficacy of dose-escalated regimens.
  • Comparison of outcomes with conventional radiotherapy and surgical series.

    • Main Results:

    • Dose escalation strategies have been developed and implemented.
    • While randomized trials demonstrating improved survival are lacking, available data suggest equivalence to surgical outcomes.
    • The reviewed evidence supports the safety and efficacy of dose escalation.

    Conclusions:

    • Dose escalation in prostate cancer radiotherapy is a viable strategy.
    • It offers survival rates comparable to surgery, providing a realistic treatment option.
    • Further research, including randomized trials, is needed to definitively establish survival benefits.